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miR-199a-5p confers tumor-suppressive
role in triple-negative breast cancer
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Abstract
Background: Triple-negative breast cancer (TNBC) remains a poor prognostic factor for breast cancer since no
effective targeted therapy is readily available. Our previous studies confirmed miR-199a-5p is a TNBC-specific circulating
biomarker, however, its functional roles in breast cancer is largely unknown. Thus, we investigated the functional
implication of miR-199a-5p in TNBC and its potential underlying mechanisms.
Methods: MTT assay was performed to investigate the cell proliferation after transient transfection of miR-199a-5p in
MDA-MB-231 cell line, followed by cell cycle analysis. Transwell invasion assay and wound healing assay were used to
study the invasion and migration ability respectively. To further investigate the stemness-related characteristics of miR-
199a-5p in breast cancer cells, single-cell clonogenic assay and aldehyde dehydrogenase (ALDH) assay were performed.
32 normal and 100 breast cancer patients’ plasma were recruited to identify the potential circulating markers by qPCR.
Results: Cell proliferation assay revealed significant inhibition after miR-199a-5p ectopic expression (p < 0.0001), as a
result of decreased S phase (p = 0.0284), increased G0/G1 phase (p = 0.0260) and apoptosis (p = 0.0374). Invasiveness
(p = 0.0005) and wound healing ability were also decreased upon miR-199a-5p overexpression. It significantly altered
EMT-related genes expression, namely CDH1, ZEB1 and TWIST. Single-cell clonogenic assay showed decreased colonies
in miR-199a-5p (p = 0.0182). Significant downregulation (p = 0.0088) and inhibited activity (p = 0.0390) of ALDH was
observed in miR-199a-5p. ALDH1A3, which is the dominant isoform of ALDH, is significantly upregulated in breast
cancer plasma especially in TNBC (p = 0.0248). PIK3CD was identified as a potential downstream target of miR-199a-5p.
Conclusions: Taken together, we unraveled, for the first time, the tumor-suppressive role of miR-199a-5p in TNBC,
which attributed to EMT and cancer stemness properties, providing a novel therapeutic options towards this
aggressive disease.
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Background
Breast cancer is one of the most frequent cancers in the
world with approximately 1.67 million new cases diag-
nosed in 2012 [Globocan 2012, http://globocan.iarc.fr/
Pages/fact_sheets_cancer.aspx]. It is the second most
common cause of cancer-related mortality among
women, accounting for over 500,000 deaths every year
[1]. Like other cancers, breast cancer is a heterogeneous
tumors originating from mammary epithelial cells with a
high degree of diversity between and within tumors as
well as among cancer-bearing individuals [2]. The clas-
sification of subtypes is widely applied in clinical set-
tings based on the human epidermal growth factor
receptor 2 (HER2) expression, hormonal receptors in-
cluding estrogen receptor (ER), progesterone receptor
(PR). They are classified into different subtypes: luminal
A (ER + and/or PR+, Ki67 low and HER2-), luminal B
(ER + and/or PR+, Ki67 high and/or HER2+), HER2-
positive (ER-, PR- and HER2+) and triple-negative (ER-,
PR-, HER2-). TNBC accounts for only 15–20% of all
breast cancer cases while exhibiting the most aggressive
biological phenotype and the metastasis rate is 35%
after 6-year follow-up [3]. Also, TNBC had an increased
likelihood of distant recurrence and mortality within
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5 years of diagnosis when compared to the non-TNBC
patients. Due to the absence of ER, PR and HER2,
TNBC is unresponsive to treatment targeting these
receptors such as Tamoxifen (an antagonist to the ER),
or Herceptin (monoclonal antibody against HER2
receptor).
MicroRNAs (miRNAs) are classified as small non-
coding regulatory RNAs (18–24 nucleotides in length)
that are emerged as central posttranscriptional repres-
sors of gene expression. MiRNAs regulate numerous
biological processes such as cell growth, development
and differentiation by determining the “on-and-off” of
the genes expression [4]. Recent studies have demon-
strated a fundamental role of miRNAs in the develop-
ment of various diseases involved different systems such
as neurology, cardiovascular, endocrine and develop-
mental diseases [5]. Alterations in miRNA expression
have been linked to the initiation and development of
cancers [6]. In clinical setting, some breast cancer pa-
tients with similar disease characteristics show different
clinical outcomes, indicating the needs for an affordable,
reliable, less invasive approach to predict the diagnosis
and prognosis of breast cancer. It has been demon-
strated that miRNAs play a role in oncogenesis, metasta-
sis, and resistance in cancer, they can be further
classified as oncogenes or tumor-suppressor genes [7–9].
Some miRNAs, for example, miR-10b, miR-21 and
miR-155 confer their oncogenic role by deactivating
tumor-suppressor genes while activating oncogenic
transcription factors in breast cancer [7, 10]. A majority
of miRNAs exhibit downregulation in breast cancer, in-
dicating their tumor-suppressive function, for example,
miR125b, miR200, miR206 [11–14]. In this regard,
miRNAs have been indicated as potential biomarkers as
they can be readily detected in breast cancer tissues
[15] and also stably expressed in human body fluids
such as plasma, serum and saliva [16].
Accumulating evidence demonstrated that miRNAs
show distinct expression signatures across different
cancer subtypes, and have either oncogenic or tumor-
suppressive roles [17, 18]. Our previous study discov-
ered that miR-199a-5p showed low expression in
TNBC patients’ circulation when compared with other
subtypes of breast cancers, also the expression level
was linked with disease stage, and suggested to be a
potential biomarker for TNBC [19]. In 2003, miR-
199a-5p was first described to be originated from two
genetic loci. One was chromosome 19 for miR-199a-1
and the other one was chromosome 1 for miR-199a-
2. It is reported that miR-199a-5p inhibited cell pro-
liferation and induced cell death [20, 21]. Based on
these findings, we sought to investigate the functional
implications of miR-199a-5p in breast cancer both in
vivo and in vitro.
Methods
Patients
We recruited 100 breast cancer patients (50 TNBC and
50 non-TNBC) from different hospitals namely Queen
Mary Hospital, the Tung Wah Hospital, the Hong Kong
Sanatorium and Hospital and the Hong Kong Hereditary
Breast Cancer Family Registry. Written consent forms
were obtained from all participating patients. The clin-
ical characteristics of patients were listed as in Table 1.
We also recruited 32 healthy individuals without per-
sonal history of cancers including breast cancer from the
Queen Mary Hospital and the Tung Wah Hospital as
normal control cases. The approval of the study was
obtained through Institutional Review Board of the
University of Hong Kong and Hong Kong Sanatorium
and Hospital (No. UW 14–441).
Cell culture and transfection
A metastatic human breast cancer cell line MDA-MB-
231 (HTB-26) was purchased from the American Type
Culture Collection (Manassas, VA) and cultured in 37°C
incubator with RPMI-1640 medium (Invitrogen, NY,
USA) supplemented with 10% fetal bovine serum. Cell
line was used in less than 6 months of continuous
Table 1 Clinical characteristics of TNBC and non-TNBC breast
cancer patients
Non-TNBC
(n = 50)
TNBC
(n = 50)
P-value
Age (mean, s.d.) 50.7 (12.5) 56.4 (14.1) 0.0346
Histological type
Grade 1, 2 28 12 0.0067
Grade 3 15 25
NA 7 13
Metastasis 0.0309
No 49 42
Yes 1 8
Stage n.s.
0, I, II 44 40
III, IV 5 10
NA 1 0
Bilateral n.s.
No 48 47
Yes 2 3
Histological type n.s.
DCIS 5 1
IDC 42 42
Mixed (IDC + ILC) 1 2
Others 2 5
DCIS ductal carcinoma in situ; IDC invasive ductal carcinoma; ILC invasive
lobular carcinoma; NA not applicable; n.s. not significant
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passage after acquisition and authenticated by the cell
bank source using short tandem repeat profiling. Cells
were transfected with Allstar Negative Control siRNA and
hsa-miRNA-199a-5p mimic (Qiagen, CA, USA) for 72 h
and collected for further studies. To develop the stable cell
line, hsa-miR-199a precursor with 200–250 bp of flanking
sequences were PCR amplified from human genomic
DNA (forward primer sequence: GACTAAGCTTAGCA
GAAGCCACGATCCCAAAC; reverse primer sequence:
GACTGGATCC GGATGGCAGACTGATAGGGC), and
cloned into the pmR-ZsGreen1 Vector (Clontech, CA,
USA). The insert was verified by Sanger Sequencing, and
the expression plasmid was transfected into MDA-MB-
231 cells using Lipofectamine 3000 (Life Technologies,
CA, USA) for miRNA expression. Stable cell clones were
selected with 0.5 mg/ml Geneticin (Life Technologies,
CA, USA), and the expression of miR-199a-5p was con-
firmed by qPCR.
Cell proliferation assay
Stable transfected cells (3×103) were seeded in a 96-well
microtiter plate with triplicate wells. After incubation for
3 days, MTT assay was used to measure cell viability
from day1 to day5, intracellular purple formazan was
solubilized in DMSO followed by the colorimetric prod-
uct quantified at absorbance 570 nm.
Migration assay
Cell migration ability was investigated using scratch
wound-healing assay. After cells reached 90% confluent
in a 6-well plate, a sterile pipette tip was used to scratch
on cell monolayer. The wound area was monitored
under microscopy (Olympus CKX41, MA, USA) and the
images were acquired for each sample at 0, 3, 9 and 12 h
by DP controller 3.31.292 (Olympus, MA, USA).
Cell invasion assay
Cell invasion assays were performed using the BD Bio-
Coat™ Matrigel™ Invasion Chamber (BD Biosciences,
MA, USA) according to the manufacturer’s instruc-
tions. Briefly, MDA-MB-231 cells were transfected
with miR-199a-5p, 3 days later, 2.5×104 cells resus-
pended in serum-free RPMI 1640 medium were placed
in the upper chambers, and chemoattractant (RPMI
1640 medium supplemented with 10% fetal bovine
serum) was placed in the lower chamber, and cells
were allowed to invade for 24 h at 37°C. Invaded cells
were fixed with 100% methanol and stained with crys-
tal violet. Invaded cells were counted at magnification
x400 from 10 random fields. All experiments were
performed in triplicates.
Single-cell clonogenic assay
Single-cell clonogenic assay was performed to investigate
the self-renewal ability in vitro. Briefly, we seeded each
well with one cell in the 96 well plates and cultured in
complete medium. The number of cell colonies (greater
than 50 cells) were counted after 7 days.
RNA extraction and quantitative RT-PCR (qRT-PCR)
Purification of total RNA was performed by using the
miRNeasy Serum/Plasma Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. Briefly, 1 ml
QIAzol Lysis Reagent was added to 200 μl plasma. Then
200 μl chloroform was added for separation followed by
adding 100% ethanol to the aqueous phase. After being
mixed thoroughly, sample was transferred into an
RNeasy MinElute spin column for centrifugation. The
concentrations of eluted RNA samples were analyzed by
NanoDrop 1000 (Thermo Scientific, DE, USA). Reverse
transcription was done by Superscript® IV Reverse Tran-
scriptase (Invitrogen, CA, USA) according to manufac-
turer’s standard protocol. Light Cycler 480 SYBR Green
I Master (Roche, Mannheim, Germany) was used to per-
form real-time qPCR in Roche LC480 machine.
Immunofluorescence
Cells were seeded on the cover slips and incubated for
24 h. Cells were washed with PBS and fixed in 2% parafor-
maldehyde for 20 min in room temperature. Then cells
were permeabilized by 0.2% triton/PBS for 10 min in
room temperature. After washing with PBS, 3% BSA/PBS
was added to cells to block the non-specific binding sites
for 45 min and incubated with anti-Twist (Abcam, Cam-
bridge, UK) or anti-E-cadherin (Cell Signaling, MA, USA)
antibody for 60 min, followed by incubation with second-
ary donkey anti-rabbit antibody (Abcam, Cambridge, UK)
for 50 min. After washing, 4′, 6-diamidino-2-phenylindole
(DAPI) was used to stain the nucleus and were observed
under immunofluorescence microscopy (Nikon, Eclipse
80i, Tokyo, Japan).
Aldehyde dehydrogenase (ALDH) activity
ALDH activity was measured by using the ALDE-
FLUOR™ Assay System (StemCell Technologies, WA,
USA) according to the manufacturer’s recommendations.
Single cells were resuspended in ALDEFLUOR™ Assay
Buffer and incubated with the activated ALDEFLUOR™
Reagent, biodipy-aminoacetaldehyde (BAAA). For nega-
tive control, an equal amount aliquot of cells was also
incubated with the activated ALDEFLUOR™ Reagent and
the specific ALDH inhibitor, diethylaminobenzaldehyde
(DEAB). After 40 min, cells were washed with PBS and re-
suspended in ALDEFLUOR™ Assay Buffer in 4°C. Cells
were analyzed using a dual laser BD FACS Calibur (BD
Biosciences, MA, USA).
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CD24-/CD44+ cell population analysis
Combinations of fluorochrome-conjugated monoclonal
antibodies against human CD44 (FITC, 555478, BD Phar-
mingen™, CA, USA) and CD24 (PE, 555428, BD Pharmin-
gen™, CA, USA) or their respective controls were added to
the cell suspension at recommended concentrations as
suggested by the manufacturer instruction and incubated
at 4°C in dark for 45 min. After incubation, cells were
fixed with 2% paraformaldehyde and analyzed using BD
FACS Calibur (BD Biosciences, MA, USA).
Cell cycle analysis
3 ml ice-cold 70% ethanol was added to fix cells at −20°
C overnight. After fixation, cell pellets were collected by
centrifugation. After washed three times by PBS, cells
were stained with 20 μg/ml propidium iodide and
0.2 mg/ml RNase A for 30 min. BD FACSCalibur (BD
Biosciences, MA, USA) was used to perform flow cy-
tometry and Cell Quest software for data analysis. The
experiments were performed in triplicates.
Apoptosis assay
Cellular apoptosis was detected by FITC Annexin V
Apoptosis Detection Kit (BD Pharmingen™, CA, USA) ac-
cording to manufacturer’s standard protocol. Briefly, cells
were suspended in 1X binding buffer at concentration of
1×106 cells/ml. 5 μl FITC Annexin V together with 5 μl PI
were added to 100 μl of resuspended cells and gently vor-
texed for 15 min at room temperature in dark. After
incubation, 400 μl 1X binding buffer was added then ana-
lyzed by BD FACSCalibur (BD Biosciences, MA, USA).
Immunohistochemistry
TWIST and CDH1 expressions were detected in
formalin-fixed, paraffin-embedded tissue sections ac-
cording to the manufacturer’s instructions. Briefly, tis-
sue sections were deparaffinized and rehydrated,
followed by an epitope retrieval step incubated in a
citrate buffer solution at 90–95°C for 10 min prior to
3% hydrogen peroxide. Slides were then blocked with
5% blocking solution for 1 h at room temperature
and incubated with anti-CDH1, (3195S, Cell Signaling
Technologies, MA, USA) and anti-TWIST (ab50581,
Abcam, Cambridge, UK) antibody overnight at 4°C.
Visualization was performed by SignalStain® Boost De-
tection Reagent (Cell Signaling Technologies, MA,
USA) for 30 min. Slide images were obtained using
an Eclipse E600 microscope (Nikon, NY, USA).
Dual-luciferase assay
Potential target genes of hsa-miR-199a-5p were pre-
dicted in silico using online algorithms, including:
miRDB (http://mirdb.org/miRDB/index.html) and miR-
map (http://mirmap.ezlab.org/). 3′-untranslated regions
(UTR) of human TGF-β2 and PIK3CD, which contain the
putative miRNA target sites, were PCR amplified (TGF-
β2-3′UTR forward primer sequence: GACTGCTAG
CTAAAATTCTTGGAAAAGTGGCA, reverse primer
Fig. 1 miR-199a-5p inhibited cell proliferation. a MTT assay showed a significant inhibition on cell proliferation in miR-199a-5p overexpression
group. b Cell cycle analysis showed a significant reduction in S phase (p = 0.0284) and increased G0/G1phase arrest (p = 0.0260). c Annexin V
analysis showed that miR-199a-5p increased early apoptosis (p = 0.0374) (ns = not significant, *P ≤ 0.05, ****P ≤ 0.0001). All experiments were
repeated in triplicates
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sequence: GACTGTCGACGGTCATATAATAACTCAC
TTGG; PIK3CD-3′UTR forward primer sequence: GA
CTGCTAGCAAGACAACAGGCAGTAGTGGCT, re-
verse primer sequence: GACTGTCGACCAGCGTAG
ATTCTCCTTT) from MDA-MB-231 cDNA and cloned
into the pmirGLO Dual-Luciferase miRNA Target Ex-
pression Vector (Promega, MI, USA) between NheI and
SalI sites. TGF-β2-, PIK3CD- and empty pmirGLO re-
porter constructs were co-transfected with miR-199a-
5p mimics or mimic negative control (Qiagen, CA,
USA), to a final concentration of 10 nM, into MDA-
MB-231 cells using Lipofectamine 3000 (Invitrogen,
CA, USA) for 48 h. Relative luciferase activities were
determined using Dual-Glo Luciferase Assay System
(Promega, MI, USA).
In vivo xenograft study
Briefly, 1×106 miR-199a-5p overexpressing cells and
control cells were injected into the nude mice fat pad.
Tumor sizes were calculated using formula 1/2(length ×
width2) every 7 days. Tumors were harvested for meas-
urement after the mice were sacrificed at week 5.
Statistical analysis
The differences between groups were estimated by
Student’s t-test, non-parametric Mann-Whitney U test,
Chi-square test as appropriate. P < 0.05 was considered as
statistically significant. All statistical analyses were per-
formed using GraphPad Prism 6.0 (GraphPad Software
Inc., San Diego, CA, USA).
Results
miR-199a-5p inhibited cell proliferation by inducing
G0/G1 phase arrest and apoptosis in breast cancer cells
To gain insight into the functional role of miR-199a-
5p in breast cancer, MDA-MB-231 cells were trans-
fected with miR-199a-5p mimic. Results showed that
miR-199a-5p significant reduced cell proliferation by
MTT assay (Fig. 1a). Cell cycle analysis showed that
miR-199a-5p overexpression led to significant
Fig. 2 miR-199a-5p inhibited cell migration and invasion ability in breast cancer cells (a, b) In vitro wound healing process was mimicked by
scratching cells surface. The rate of migration was measured by quantifying the total distance that the cells moved from the edge of the scratch
toward the center of the scratch (marked by imaginary lines). Cells were observed under x200 microscope at different time points (0, 3, 9 and
12 h. c, d Transwell invasion assay showed miR-199a-5p significant decreased the number of invasive cells (52 vs 33 cells per x400 field in control
and miR-199a-5p mimic group, p = 0.0005). e Ectopic expression of miR-199a-5p significantly upregulated CDH1 expression and downregulated
ZEB1, TWIST expression. All experiments were repeated in triplicates
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decrease in S-phase (p = 0.0284) and caused G0/G1
phase arrest (p = 0.0260) (Fig. 1b). Ectopic expression
of miR-199a-5p showed significantly increased in early
apoptosis (p = 0.0374) while no significant difference
observed in late apoptotic cells (Fig. 1c).
miR-199a-5p significantly inhibited cell migration and
invasion ability in breast cancer cells through epithelial-
mesenchymal transition (EMT) process
To study the effect of miR-199a-5p on EMT process,
wound healing and invasion assays were assessed. In
wound healing assay, the cell migration ability was sig-
nificantly inhibited in miR-199a-5p overexpressing cells
when compared with the control at different time
points (3, 9, 12 h) (Fig. 2a & b). Invasion assay also
demonstrated a profound decreased number of invasive
cells in miR-199a-5p overexpressing cells (p = 0.0005)
(Fig. 2c & d). Overexpression of miR-199a-5p altered
the expression levels of EMT-related markers such as
CDH1 (E-cadherin), ZEB1 and TWIST (Fig. 2e).
Immunofluorescent staining result showed that miR-
199a-5p induced obvious TWIST translocation from
nucleus to cytoplasm (p = 0.0002) and profound CDH1
expression compared to the control group (p = 0.0015)
(Fig. 3a, b). These results indicating that miR-199a-5p
suppressed EMT process in breast cancer.
miR-199a-5p inhibited stem-cell like properties in breast
cancer cells
In order to explore the potential role of miR-199a-5p
in stemness features, we examined the effect of miR-
199a-5p in single-cell clonogenic assay. Ectopic ex-
pression of miR-199a-5p reduced the number of
colonies (p = 0.0182) and their sizes, implicating the
tumor suppressive role of miR-199a-5p on self-renewal
ability (Fig. 4a). We further confirmed that ALDH ac-
tivity significantly decreased in miR-199a-5p overex-
pressing cells (p = 0.039) when compared to control,
indicating that miR-199a-5p played a role in stemness
properties in breast cancer (Fig. 4b). Also, ALDH1A3
expression was lowered in miR-199a-5p mimic trans-
fected cells (p = 0.0088) (Fig. 4c). We also confirmed
that miR-199a-5p significantly decreased the CD24-/
CD44+ cell population (p = 0.0015) (Fig. 4d), which is a
well-reported subpopulation of breast cancer cells to
have stem/progenitor cell properties. In line with the
finding in vitro, miR-199a-5p overexpressing mice had
smaller tumors than control mice (Fig. 4e). MiR-199a-
5p downregulated TWIST and led to translocation
from nucleus to cytoplasm, and induced CDH1 expres-
sion in xenograft tissues by immunostaining (Fig. 4f ).
Moreover, ALDH1A3 significantly upregulated in the
plasma of breast cancer patients, especially in TNBC when
Fig. 3 Immunofluorescent staining of TWIST (a) and CDH1 (b) in MDA-MB-231 and miR-199a-5p mimic. The result showed that miR-199a-5p in-
duced obvious TWIST translocation from nucleus to cytoplasm (p = 0.0002) and more profound CDH1 expression compared to the control group
(p = 0.0015). (*P≤ 0.05, ***P≤ 0.001). All experiments were repeated in triplicates
Chen et al. BMC Cancer  (2016) 16:887 Page 6 of 12
compared with normal control (Normal control vs breast
cancer, p = 0.0135; non-TNBC vs TNBC, p = 0.0248)
(Fig. 5a, b). Further stratification by clinical-pathological
data showed that ALDH1A3 expression correlated with
higher histological grade (p = 0.0355) and more advanced
disease stage (p = 0.0368) (Fig. 5c, d). All these findings
indicate that miR-199a-5p is related to stemness features
in TNBC through regulation of ALDH1A3.
miR-199a-5p influenced expression of TGF-β2 and PIK3CD
in breast cancer
For identification of potential downstream targets of
miR-199a-5p, several online prediction tools (miRDB,
miRMAP) were used. All the predicted targets have pre-
diction scores range from 50 to 100. These scores are
assigned by the computational target prediction algo-
rithm. Putative miR-199a-5p targets, PIK3CD and TGF-
β2, were selected based on their high scores in all these
two prediction tools (score: 94-99).
MiR-199a-5p mimic significantly downregulated TGF-
β2 (p = 0.0317) and PIK3CD expression (p = 0.0079) in
MDA-MB-231 breast cancer cell line (Fig. 6a, b). By dual
luciferase reporter assay, mimic of miR-199a-5p de-
creased the relative luciferase activity in a greater ex-
tend in MDA-MB-231 transfected with reporter
constructs containing the 3′-UTRs of PIK3CD and
TGF-β2 compared to the empty construct controls
(Fig. 6c, d) (p = 0.0341 in TGF-β2 group, p = 0.0028 in
PIK3CD group), indicating TGF-β2 and PIK3CD are
the direct downstream targets of miR-199a-5p.
Fig. 4 miR-199a-5p inhibited stem-cell like properties in breast cancer cells (a) Ectopic expression of miR-199a-5p reduced the single cell colony
formation ability in MDA-MB-231 breast cancer cells (p = 0.0182). Single-cell clonogenic assay was used to determine single cell colony formation
ability, cell clones reached more than 50 cells were considered as cell colonies. Representative micrographs (left panel) of colonies in single-cell
clonogenic assay. b ALDH activity assay showed a significant reduced ALDH-positive cell population in miR-199a-5p mimic group than in the
control group (17.2% vs 10.7%, p = 0.039). c ALDH1A3 expression was significantly suppressed after miR-199a-mimic treatment (p = 0.0088).
d CD24-/CD44+ cell population showed significant decrease in miR-199a-5p overexpressing cells compared to its control group (p = 0.0015).
e miR-199a-5p inhibited in vivo tumor growth. Left panel: three represented nude mice showed the reduction of tumor growth by overexpression
of miR-199a-5p (control: left side, miR-199a-5p: right side). Right panel demonstrated the increase in volume of xenograft in the miR-199a-5p group.
f Immunohistochemistry staining of mice xenograft from fat pad injection with MDA-MB-231 miR-199a-5p stable cells. (*P≤ 0.05, **P≤ 0.01). All
experiments were repeated in triplicates
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We further examined the gene expression in plasma of
breast cancer patients. Results suggested that PIK3CD
expression were higher in the circulation (p = 0.0453)
(Fig. 7a) and TGF-β2 had no observable changes (Fig. 7b)
in breast cancer patients when compared to normal
control. However, neither genes exhibited significant dif-
ferent expression between non-TNBC and TNBC. The
results indicated that PIK3CD is associated with breast
cancer.
Discussion
Our previous study demonstrated that miR-199a-5p ex-
pression was downregulated in TNBC when compared
to other subtypes [19]. However, the functional roles and
potential mechanism are still remained largely elusive.
Our results also demonstrated that miR-199a-5p re-
tarded proliferation, migration, invasion and stem cell-
like characteristics in breast cancer. Recent studies
revealed that miR-199a-5p exhibited downregulation and
tumor-suppressive role in various types of cancers both
in vitro and in vivo [22]. Our cell cycle and apoptosis
assay results indicated that decreased S phase cells, G0/
G1 phase arrest and enrichment of late apoptotic cells
may be the potential mechanisms of the inhibitory role
of miR-199a-5p. Accumulating evidence have established
an important relationship between EMT and the acquisi-
tion of molecular and functional characteristics of cancer
stem cells [23, 24]. The reduction of migration and
invasion ability may be partly due to the altered EMT-
related signaling, such as CDH2 by regulating transcrip-
tional factor SNAI1 [25]. Similar observation was found
in breast cancer cells, we discovered that miR-199a-5p
greatly suppressed the migration and invasion ability.
Some EMT-related genes such as CDH1, ZEB1 and
TWIST were significantly altered by the introduction of
miR-199a-5p in MDA-MB-231 cells, implicating the
possibility of EMT process involvement. TWIST has
been considered as a critical EMT inducer which allows
the acquisition of mesenchymal phenotype that permit
the invasion and metastasis from the primary tumor site
[26, 27]. TWIST expression caused the inhibition of
CDH1 and promoted the expression of fibroblastic
markers such as fibronectin, smooth-muscle actin and
vimentin [28, 29]. In gastric cancer, a high TWIST pro-
tein expression level was associated with a reduction in
CDH1 protein and with the increased CDH2 which may
enhance cell motility in several cancer types [29]. Con-
sistent with the above findings, our result shed light into
Fig. 5 Expression of ALDH1A3 in 32 normal control and 100 breast cancer patients’ plasma. a, b Expression of ALDH1A3 significant elevated in
breast cancer plasma (p < 0.0001), especially in TNBC. c, d ALDH1A3 significantly upregulated in breast cancer cases with higher histological grade
(grade 3) (p = 0.0355) and more advanced disease stage (stage II, III, IV) (p = 0.0368). (*P ≤ 0.05, **P≤ 0.01)
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the potential mechanism of the miR-199a-5p induced in-
hibition on migration/invasion through EMT in breast
cancer.
It has been well accepted that not all cells within tumor
are identical and that in a number of different cancers,
such as teratocarcinoma, a small sub-population of cancer
cells possess “stem-like” characteristics including self-
renewal, tumorigenicity, which defined as cancer stem
cells (CSCs). In breast cancer, EMT has been associated
with CSCs characteristics including self-renewal ability
and the expression of stem cell-associated cell subpopula-
tion CD44+/CD24–/low [30]. Regarding the miR199-5p-
induced EMT alteration in breast cancer, we further look
into the stemness features related to miR-199a-5p.
Single cell colony formation assay showed less and
smaller colonies in miR-199a-5p group, suggesting its
suppressive role in self-renewal. In recent years, tumor-
initiating cells (TICs), have been widely implicated in
different treatment-resistant tumors [31–33]. Recent
evidence suggests that enhanced ALDH activity serves
as a hallmark of CSCs measurable by the aldefluor
assay. In breast cancer, the CSCs enriched in ALDH-
positive cells isolated from human breast tumors were
with high self-renewal and tumorigenic activity [34], in-
dicating ALDH activity is an important and promising
tool for the study of stem cells properties. We managed
to discover that miR-199a-5p significantly reduced the
CSCs/TICs population, which reflected by decline of
the ALDH-positive cells. More recent findings identi-
fied that ALDH isoforms, particularly ALDH1A3, con-
tributed to ALDH activity in breast CSC [35]. It has
been widely reported that CD24-/CD44+ are the two
cell surface markers used for isolating tumorigenic CSC
from non-tumorigenic cancer cells [36, 37]. Our results
demonstrated that miR-199a-5p indeed inhibited the
breast cancer cell stemness by decreasing the CD24-/
CD44+ population and ALDH activity.
Recent studies have suggested the possible relationship
between miRNA deregulation and drug resistance. Pre-
clinical models have proved that microRNA-based treat-
ment work as an effective strategy in cancer treatment.
MiR-451 and miR-27 have been implicated in the devel-
opment of doxorubicin resistance [38, 39] while miR-
326 was found to be associated with sensitivity to several
chemotherapeutic drugs in breast cancer [40]. Recent
studies have revealed that cisplatin treatment de-
creased miR-199a-5p expression in HCC patients,
which may account for chemoresistance. Forced ex-
pression of miR-199a-5p promoted cisplatin-induced
inhibition of cell proliferation, resulting sensitization
Fig. 6 TGF-β2 and PIK3CD are potential downstream targets of miR-199a-5p. a, b Transient transfection of miR-199a-5p in MDA-MB-231 cell line
significantly impeded TGF-β2 (p = 0.0317) and PIK3CD expression (p = 0.0079). c, d Luciferase reporter assay led to more profound reduction
luciferase activity level of TGF-β2 (p = 0.0341) and PIK3CD (p = 0.0028) in miR-199a-5p mimic group than control group. (*P ≤ 0.05, **P ≤ 0.01).
All experiments were repeated in triplicates
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of cancer cells to chemotherapy [41]. Also, miR-199a-
5p is related to multidrug resistance in colon cancer
[42] and it is upregulated in cisplatin-sensitive ovarian
cancer cells [43]. In this study, we have established a
robust tumor-suppressive role of miR-199a-5p in
TNBC via modulation of EMT genes and stem cancer
markers, further investigation effort should be placed
on the altered chemotherapy sensitivity and hence
might help in selecting a more suitable chemothera-
peutic agent.
Conclusions
Taken together, our results demonstrated that the
TNBC-associated biomarker miR-199a-5p conferred
tumor-suppressive role in breast cancer by regulating
EMT process and stemness characteristics. Furthermore,
ALDH1A3 may be a potential TNBC-specific candidate
gene, which providing novel treatment options for breast
cancer. However, further intensive investigation is
needed to confirm its role in breast cancer.
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